Toward predictors of survival in castration-resistant prostate cancer

Cancer

Volumn 117, Issue 17, 2011, Pages 3882-3884

  Graff, Julie N ^a   Beer, Tomasz M ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; CYTOTOXIC AGENT; DOCETAXEL; MITOXANTRONE; PROSTATE SPECIFIC ANTIGEN;

BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER GRADING; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER PAIN; CANCER RESISTANCE; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; HUMAN; LYMPH NODE METASTASIS; METASTASIS POTENTIAL; OVERALL SURVIVAL; PRACTICE GUIDELINE; PREDICTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; PROSTATE ADENOCARCINOMA; RETROSPECTIVE STUDY; REVIEW; SOFT TISSUE METASTASIS; SOFT TISSUE TUMOR; THERAPY EFFECT; TREATMENT RESPONSE;

HUMANS; MALE; PROSTATIC NEOPLASMS;

EID: 80051939662     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25986     Document Type: Review

References (13)

1. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92: 205-216.
2. Scher HI, Morris MJ, Kelly WK, Schwartz LH, Heller G,. Prostate cancer clinical trial end points: "RECIST"ing a step backwards. Clin Cancer Res. 2005; 11: 5223-5232. (Pubitemid 41003710)
3. Scher HI, Halabi S, Tannock I, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008; 26: 1148-1159.
4. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004; 351: 1502-1512. (Pubitemid 39315317)
5. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004; 351: 1513-1520. (Pubitemid 39315318)
6. Petrylak DP, Ankerst DP, Jiang CS, et al. Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. J Natl Cancer Inst. 2006; 98: 516-521. (Pubitemid 43898814)
7. Armstrong AJ, Garrett-Mayer ES, Yang YC, de Wit R, Tannock IF, Eisenberger M,. A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis. Clin Cancer Res. 2007; 13: 6396-6403. (Pubitemid 350075029)
8. Scher HI, Warren M, Heller G,. The association between measures of progression and survival in castrate-metastatic prostate cancer. Clin Cancer Res. 2007; 13: 1488-1492. (Pubitemid 46450439)
9. Scher HI, Jia X, de Bono JS, et al. Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data. Lancet Oncol. 2009; 10: 233-239.
10. Armstrong AJ, Garrett-Mayer E, Ou Yang YC, et al. Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer. J Clin Oncol. 2007; 25: 3965-3970. (Pubitemid 47477275)
11. Higano CS, Schellhammer PF, Small EJ, et al. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer. 2009; 115: 3670-3679.
12. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010; 363: 411-422.
13. Sonpavde G, Pond GR, Berry WR, et al. The association between radiographic response and overall survival in men with metastatic castration-resistant prostate cancer receiving chemotherapy. Cancer. 2011; 117: 3963-3971.